Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.56 |
| ▸ | PDE4A | P27815 | 10/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926106 | 0.93 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL2930368 | 0.89 | LTC4S (0.45) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2930370 | 0.88 | MAPT (0.44) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2926110 | 0.88 | HTT (0.43) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1157297 | 0.86 | PDE4D (0.54) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL2931281 | 0.86 | PDE4A (0.54) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2924647 | 0.86 | PDE4D (0.50) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL2932689 | 0.85 | ALDH1A1 (0.42) | — | |
| SCHEMBL2927444 | 0.84 | PDE4D (0.51) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL3131858 | 0.83 | PDE4D (0.52) | PDE4DPDE4BPDE4APDE4CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | claimed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | claimed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | claimed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | claimed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | disclosed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | disclosed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | PDE4A, PDE4B, PDE3B | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.